Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Yellow fever vaccine (produced on serum-free Vero cells), Yellow fever vaccine (live)
Yellow fever vaccine · 3 trials · 2 indications
Seroconversion rates will be assessed using a YF MN assay Seroconversion is defined as a 4-fold increase in neutralizing Ab (NAb) titers as compared to the pre-vaccination value (Day 01)
Seroconversion rates will be assessed using a YF MN assay Seroconversion is defined as a 4-fold increase in NAb titers as compared to the pre-vaccination value
Seroconversion rates will be assessed using a YF MN assay Seroconversion is defined as a 4-fold increase in NAb titers as compared to the pre-vaccination value
Seroconversion rates will be assessed using a YF MN assay Seroconversion is defined as a 4-fold increase in NAb titers as compared to the pre-vaccination value
Seroconversion rates will be assessed using a YF MN assay Seroconversion is defined as a 4-fold increase in NAb titers as compared to the pre-vaccination value
Immediate adverse events are any unsolicited systemic adverse events reported in the 30 minutes after vaccination
Solicited injection site reactions include injection site pain, erythema and swelling
Solicited systemic reactions include fever, headache, malaise and myalgia
Unsolicited (spontaneously reported) AEs, not fulfilling criteria for solicited adverse reactions
MAAEs
AESIs
SAEs
| Arm | Type | Description |
|---|---|---|
| vYF | EXPERIMENTAL | One single dose of vYF will be administered subcutaneously at the 1st visit |
| Group 1 (9-24 months) | EXPERIMENTAL | Primary vaccination phase: 1 injection of vYF vaccine at Day 1 Booster phase: 1 injection of vYF vaccine at Year 3 (in a subset) |
| Group 2 (9-24 months) | ACTIVE_COMPARATOR | Primary vaccination phase: 1 injection of Stamaril vaccine at Day 1 Booster phase: 1 injection of Stamaril vaccine at Year 3 (in a subset) |
| Group 3 (9-24 months) | ACTIVE_COMPARATOR | Primary vaccination phase: 1 injection of YF-VAX vaccine at Day 1 Booster phase: 1 injection of YF-VAX vaccine at Year 3 (in a subset) |
| Group 4 (2-5 years) | EXPERIMENTAL | Primary vaccination phase: 1 injection of vYF vaccine at Day 1 |
| Group 5 (2-5 years) | ACTIVE_COMPARATOR | Primary vaccination phase: 1 injection of Stamaril vaccine at Day 1 |
| Group 6 (2-5 years) | ACTIVE_COMPARATOR | Primary vaccination phase: 1 injection of YF-VAX vaccine at Day 1 |
| Group 7 (approximately 11-15 months) | EXPERIMENTAL | Primary vaccination phase: 1 injection of MMR vaccine at Day 1 in a cohort of 11 to 15 months of age vaccinated with vYF |
| vYF vaccine | EXPERIMENTAL | A single dose on Day 01 |
| YF-VAX vaccine | ACTIVE_COMPARATOR | A single dose on Day 01 |
| Name | Type | Description |
|---|---|---|
| Yellow fever vaccine (live) | BIOLOGICAL | Pharmaceutical form:Powder and diluent for suspension for injection-Route of administration:Subcutaneous |
| Measles, combinations with mumps and rubella, live attenuated | BIOLOGICAL | Powder, lyophilized, for suspension for reconstitution Subcutaneous or intermuscular |
| YF vaccine (live) | BIOLOGICAL | Powder and diluent for suspension for injection Subcutaneous |
Inclusion Criteria: * Aged from 18 years on the day of inclusion\* \* "From 18 years" means from the day of the 18th birthday * Participants who are healthy as determined by medical evaluation including medical history and physical examination. * Able to attend all scheduled visits and to comply...
Yellow Fever vaccine is used for immunization against yellow fever, a viral infection transmitted by mosquitoes. It is also being studied for use in dengue prevention. The vaccine is indicated for yellow fever immunization in adults and pediatric populations, and clinical trials are evaluating its safety and immunogenicity.
Sanofi (ticker: SNY) is developing the Yellow Fever vaccine. The vaccine is produced on serum-free Vero cells and is a live attenuated vaccine. Sanofi is conducting Phase 3 clinical trials to evaluate its safety and immunogenicity in various populations.
Yellow Fever vaccine is in Phase 3 clinical development. Multiple Phase 3 trials are ongoing or completed, including studies in adults and pediatric populations. The vaccine is investigational and not yet approved for widespread use.
Yellow Fever vaccine is being studied in several clinical trials. NCT07103148 is a Phase 3 study in pediatric populations in Honduras, Mexico, and Panama. NCT07002060 and NCT07222059 are Phase 3 studies in adults. NCT01488890 is a Phase 2 study evaluating immune response with a dengue vaccine.
Yes, Yellow Fever vaccine is also known as yellow fever vaccine (produced on serum-free Vero cells) and yellow fever vaccine (live). These names refer to the same investigational vaccine being developed by Sanofi for yellow fever immunization.
Yellow Fever vaccine is a live attenuated vaccine, meaning it contains a weakened form of the yellow fever virus. This stimulates the immune system to produce a protective response without causing the disease. It is being studied for its ability to provide immunity against yellow fever and potentially cross-protect against dengue.